IP Library Granted Patent US 7,524,855
Granted Patent B2
US 7,524,855 · App. 11/813,241 · Granted Apr 28, 2009

Selected benzofuran derivatives

Assignee: Arpida AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,524,855
App. No.
11/813,241
Granted
Apr 28, 2009
Kind
B2
Abstract

The invention relates to new benzofuran derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds, and especially their use as anti-infectives.

Claims (83)

1. A compound of Formula I,

wherein

R 1 represents

wherein R 5 is cyano, carboxylic acid or the group

wherein

R 9 represents hydrogen, lower alkyloxy, lower alkylamino, lower alkyl with 1 to 6 carbon atoms, aminocarbonylalkyl, mono- or dialkylaminoalkyl, alkyloxyalkyl, arylalkyl, aryl, or heteroaryl, wherein the aryl and heteroaryl groups can be optionally mono-, di-, or tri-substituted with straight or branched chain lower alkyl with 1 to 4 carbon atoms, wherein these substituents may be the same or different;

R 10 represents hydrogen, or lower alkyl with 1 to 4 carbon atoms; or

R 9 and R 10 together with the nitrogen atom to which they are attached, form a 3-, 4-, 5- or 6- membered heterocyclic ring, wherein the 5- or 6-membered ring optionally contains an additional heteroatom selected from the group consisting of oxygen, nitrogen and sulfur, wherein, if the additional heteroatom is nitrogen, the additional nitrogen can be substituted with lower alkyl with 1 to 4 carbon atoms, mono- or dialkylaminoalkyl or alkyloxyalkyl;

R 6 represents hydrogen, halogen, straight or branched chain lower alkyl with 1 to 4 carbon atoms, or lower alkyloxy;

R 7 represents hydrogen or halogen; and

R 8 represents hydrogen or straight or branched chain lower alkyl with 1 to 4 carbon atoms;

R 2 and R 3 independently represent hydrogen, lower alkyl with 1 to 3 carbon atoms; or together a lower alkylene group with 1 to 3 carbon atoms bridging the oxygen atoms and forming a five, six or seven membered ring; and

R 4 represents hydrogen or lower alkyl with 1 to 4 carbon atoms,

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , represented by Formula II,

wherein

R 2 and R 3 represent methyl; and

R 4 represents hydrogen.

3. The compound of claim 1 , represented by Formula III,

wherein

R 2 and R 3 represent methyl; and

R 4 represents hydrogen.

4. The compound of claim 1 , represented by Formula IV,

wherein

R 2 and R 3 represent methyl; and

R 4 represents hydrogen.

5. The compound of claim 1 , represented by Formula V,

wherein

R 2 and R 3 represent methyl; and

R 4 represents hydrogen.

6. The compound of claim 1 , represented by Formula VI,

wherein

R 2 and R 3 represent methyl; and

R 4 represents hydrogen.

7. The compound of claim 1 ,

wherein

R 5 is carboxylic acid dimethylamide, carboxylic acid methylamide, carboxylic acid diethylamide, carboxylic acid methoxyethylamine, pyrrolidin-1-yl-methanone, morpholin-4-yl-methanone, carboxylic acid methylamide, piperidin-1-yl-methanone; carboxylic acid N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-amide, carboxylic acid N-methyl-benzyl-amide 4-(2-methoxy-ethyl)-piperazin1-yl-methanone, 4-(2-dimethylamino-ethyl)-piperazin1-yl-methanone, carboxylic acid N-(2-dimethylamino-ethyl)-N-methyl-amide, carboxylic acid N-butyl- N-methyl-amide, carboxylic acid N-isopropyl-N-methyl-amide, carboxylic acid N-carbamoylmethyl-N-methyl-amide, carboxylic acid, or cyano;

R 6 represents hydrogen, fluoro, chloro or methoxy;

R 7 represents hydrogen, fluoro or chloro; and

R 8 represents hydrogen or methyl.

8. A compound selected from the group consisting of:

(4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-phenyl)-pyrrolidin-1-yl-methanone;

4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}N,N-diethyl-benzamide;

(4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}phenyl)-piperidin-1-yl-methanone;

4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-benzamide;

N-Benzyl-4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran -2-ylmethyl]-amino}-N -methyl-benzamide;

4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-N,N-dimethyl-benzamide;

5-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-N,N-dimethyl-benzamide;

4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-methyl-amino}-N,N-dimethyl-benzamide;

4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-methyl-amino}-N-methyl-benzamide;

2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-methyl-amino}-4-fluoro-N,N-dimethyl-benzamide;

2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-5,N,N-trimethyl-benzamide;

2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-6-fluoro-N,N-dimethyl-benzamide;

2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-N,N-dimethyl-benzamide;

2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-4-fluoro-N,N-dimethyl-benzamide;

3-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-N,N-dimethyl-benzamide;

3,5-Dichloro-2-[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethoxy]-N,N-dimethyl-benzamide;

4-Chloro-2-[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethoxy]-N-methyl-benzamide;

2-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethoxy]-5-fluoro-N,N-dimethyl-benzamide;

2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-3-methoxy-N,N-dimethyl-benzamide;

2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-methyl-amino}-N,N-dimethyl-benzamide;

3,6-Dichloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-N,N-dimethyl-benzamide;

4-Chloro-2-[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethoxy]-N,N-dimethyl-benzamide;

(4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-phenyl)-morpholin-4-yl-methanone;

(4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-benzonitrile;

4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-N-isopropyl-N-methyl-benzamide;

N-Butyl-4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-N-methyl-benzamide;

4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]amino}-benzoic acid;

4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-N-(2-dimethylamino-ethyl)-N-methyl-benzamide;

4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-phenyl)-[4-(2-dimethylamino-ethyl)-piperazin-1-yl]-methanone;

(4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-phenyl)-[4-(2-methoxy-ethyl)-piperazin-1-yl]-methanone; and

N-Carbamoylmethyl-4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]amino}-N-methyl-benzamide,

or a pharmaceutically acceptable salt thereof.

9. A compound represented by formula X, XVI or XVII,

wherein

R 2 and R 3 independently represent hydrogen, lower alkyl with 1 to 3 carbon atoms; or together a lower alkylene group with 1 to 3 carbon atoms bridging the oxygen atoms and forming a five, six or seven membered ring;

R 4 represents hydrogen or lower alkyl with 1 to 4 carbon atoms;

R 11 represents straight or branched chain lower alkyl; and

R 12 represents lower alkyl or aryl.

10. A pharmaceutical composition comprising one or more compounds of any one of claims 1 to 8 and an inert carrier.

11. A process for the manufacture of a pharmaceutical composition comprising one or more compounds as claimed in any one of claims 1 to 8 as an active ingredient, which process comprises mixing one or more active ingredients with a pharmaceutically acceptable med carrier or an adjuvant, or both.

12. A method for treating a bacterial infection caused by a bacterium that can be inhibited through inhibition of its dihydrofolate reductase enzyme comprising administering to a subject in need thereof the pharmaceutical composition of claim 10 .

13. The method of claim 12 , wherein said bacterial infection is caused by a Gram positive or Gram negative pathogen, or by a mixture thereof.

Assignments (2)
MERGER Recorded Apr 22, 2010
From: ARPIDA AG
To: EVOLVA SA
Reel/Frame 024272/0538 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2007
From: GREIVELDINGER-POENARU, SORANA; ISLAM, KHALID; GILLESSEN, DIETER; BURRI, KASPAR
To: ARPIDA AG
Reel/Frame 019579/0085 →
Priority Claims (1)
WO PCT/EP2005/000072 · Jan 7, 2005 · international
Continuity (1)
Related Publication 20080108610A1 · May 8, 2008